−0.5317USD
−23.88 MUSD
5.64 MUSD
49.75 M
About Evogene Ltd.
Sector
Industry
CEO
Ofer Haviv
Website
Headquarters
Rehovot
Employees (FY)
142
Founded
1999
ISIN
IL0011050551
FIGI
BBG000TGYG90
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of EVGN is 0.6570 USD — it has increased by 2.52% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Evogene Ltd. stocks are traded under the ticker EVGN.
Evogene Ltd. is going to release the next earnings report on May 28, 2024. Keep track of upcoming events with our Earnings Calendar.
EVGN stock is 2.96% volatile and has beta coefficient of 1.98. Check out the list of the most volatile stocks — is Evogene Ltd. there?
One year price forecast for Evogene Ltd. has a max estimate of 3.0000 USD and a min estimate of 1.8500 USD.
EVGN earnings for the last quarter are −0.08 USD per share, whereas the estimation was −0.16 USD resulting in a 48.94% surprise. The estimated earnings for the next quarter are −0.14 USD per share. See more details about Evogene Ltd. earnings.
Evogene Ltd. revenue for the last quarter amounts to 3.77 M USD despite the estimated figure of 1.20 M USD. In the next quarter revenue is expected to reach 475.00 K USD.
Yes, you can track Evogene Ltd. financials in yearly and quarterly reports right on TradingView.
EVGN stock has fallen by 11.35% compared to the previous week, the month change is a 17.88% fall, over the last year Evogene Ltd. has showed a 8.35% increase.
EVGN net income for the last quarter is −6.60 M USD, while the quarter before that showed −3.98 M USD of net income which accounts for −65.69% change. Track more Evogene Ltd. financial stats to get the full picture.
Today Evogene Ltd. has the market capitalization of 32.41 M, it has increased by 4.29% over the last week.
No, EVGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, EVGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Evogene Ltd. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 142.00 employees. See our rating of the largest employees — is Evogene Ltd. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Evogene Ltd. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Evogene Ltd. stock shows the strong sell signal. See more of Evogene Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Evogene Ltd. future price: according to them, EVGN price has a max estimate of 3.00 USD and a min estimate of 1.85 USD. Read a more detailed Evogene Ltd. forecast: see what analysts think of Evogene Ltd. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Evogene Ltd. EBITDA is −23.90 M USD, and current EBITDA margin is −421.61%. See more stats in Evogene Ltd. financial statements.